Nilotinib capsules are a tyrosine kinase inhibitor, which is mainly used clinically for adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in the chronic or accelerated phase who are resistant or intolerant to previous treatments (including imatinib).
The main ingredient of Nilotinib capsules is nilotinib, which can inhibit BCR-ABL tyrosine kinase in CML cells, preventing their further growth, spread and division.